The UICC and WHO will negotiate for cheaper cancer drugs for low and low-middle-income countries via increased donations, tier pricing, or a voluntary licence mechanism.
Pharmaceutical companies will be forced to disclose their drug development costs, including for cancer therapies, under the drug price transparency mechanism, says Khairy Jamaluddin.
Proposed medicine price controls are estimated to result in a loss of about RM8 billion to Malaysia’s medical tourism industry by 2037, according to a cost-benefit analysis.
A cost-benefit analysis estimates T20 patients with private insurance may save RM1.6 billion yearly, four times higher than RM368 million for M40 and 22 times higher than RM73 million for B40.
A cost-benefit analysis finds drug price controls may shutter 2,600 clinics and cause pay cuts, salary freezes, or layoffs of 91,000 to 136,000 private health care jobs.